APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-inflammatory Therapeutics

Anti-inflammatory therapeutics are treatments for arthritis, respiratory diseases, dermatology, psoriasis, inflammatory bowel disease and other inflammatory diseases. The treatments include anti-inflammatory biologics, NSAIDs, corticosteroids and others.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anti-inflammatory therapeutics are treatments for arthritis, respiratory diseases, dermatology, psoriasis, inflammatory bowel disease and other inflammatory diseases. The treatments include anti-inflammatory biologics, NSAIDs, corticosteroids and others.

Selected research

Market Outlook & Growth Opportunities

Global Anti-inflammatory Therapeutics Market Outlook and Growth Opportunities 2026

1 January 2026197 pages

Choose your research edition.

Industry ResearchAnti-inflammatory Therapeutics Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-inflammatory Therapeutics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Anti-inflammatory Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-inflammatory Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-inflammatory Therapeutics Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Anti-inflammatory therapeutics are treatments for arthritis, respiratory diseases, dermatology, psoriasis, inflammatory bowel disease and other inflammatory diseases. The treatments include anti-inflammatory biologics, NSAIDs, corticosteroids and others.

Top 5 manufacturers make up the major market share in the anti-inflammatory therapeutics market. AbbVie maintained its first place in the ranking in 2019, accounted for 21.59% market share. Other players accounted for 14.20%, 5.43%, 5.32% including Johnson & Johnson, Amgen Inc, AstraZeneca PLC.

This report provides an overview of the global Anti-inflammatory Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Anti-inflammatory Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-inflammatory Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-inflammatory Therapeutics market.

Anti-inflammatory Therapeutics Segment by Company

AbbVie

Johnson & Johnson

Amgen Inc

AstraZeneca PLC

Pfizer, Inc

Novartis

Roche

Merck

Sanofi

GlaxoSmithKline

Sun Pharmaceutical Industries Ltd

TEVA

Anti-inflammatory Therapeutics Segment by Type

Anti-inflammatory Biologics

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Corticosteroids

Others

Anti-inflammatory Therapeutics Segment by Application

Arthritis

Respiratory Diseases

Dermatology

Gastroenterology

Others

Anti-inflammatory Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-inflammatory Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-inflammatory Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Anti-inflammatory Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-inflammatory Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-inflammatory Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-inflammatory Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-inflammatory Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-inflammatory Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-inflammatory Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-inflammatory Therapeutics industry.

Chapter 3: Detailed analysis of Anti-inflammatory Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-inflammatory Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-inflammatory Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-inflammatory Therapeutics Industry Trends Table 2. Anti-inflammatory Therapeutics Industry Drivers Table 3. Anti-inflammatory Therapeutics Industry Opportunities and Challenges Table 4. Anti-inflammatory Therapeutics Industry Restraints Table 5. Global Anti-inflammatory Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-inflammatory Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Anti-inflammatory Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-inflammatory Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Anti-inflammatory Therapeutics Company, Product Type & Application Table 10. Global Anti-inflammatory Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-inflammatory Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anti-inflammatory Biologics Table 15. Significant Companies of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Table 16. Significant Companies of Corticosteroids Table 17. Significant Companies of Others Table 18. Global Anti-inflammatory Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Anti-inflammatory Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Anti-inflammatory Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Anti-inflammatory Therapeutics Sales Value Share by Type (2021-2026) Table 22. Global Anti-inflammatory Therapeutics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Arthritis Table 24. Significant Companies of Respiratory Diseases Table 25. Significant Companies of Dermatology Table 26. Significant Companies of Gastroenterology Table 27. Significant Companies of Others Table 28. Global Anti-inflammatory Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anti-inflammatory Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Anti-inflammatory Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Anti-inflammatory Therapeutics Sales Value Share by Application (2021-2026) Table 32. Global Anti-inflammatory Therapeutics Sales Value Share by Application (2027-2032) Table 33. Global Anti-inflammatory Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-inflammatory Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Anti-inflammatory Therapeutics Sales Value Share by Region (2021-2026) Table 36. Global Anti-inflammatory Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Anti-inflammatory Therapeutics Sales Value Share by Region (2027-2032) Table 38. Global Anti-inflammatory Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anti-inflammatory Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Anti-inflammatory Therapeutics Sales Value Market Share by Country (2021-2026) Table 41. Global Anti-inflammatory Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Anti-inflammatory Therapeutics Sales Value Market Share by Country (2027-2032) Table 43. AbbVie Company Information Table 44. AbbVie Business Overview Table 45. AbbVie Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. AbbVie Anti-inflammatory Therapeutics Product Portfolio Table 47. AbbVie Recent Development Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Anti-inflammatory Therapeutics Product Portfolio Table 52. Johnson & Johnson Recent Development Table 53. Amgen Inc Company Information Table 54. Amgen Inc Business Overview Table 55. Amgen Inc Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Amgen Inc Anti-inflammatory Therapeutics Product Portfolio Table 57. Amgen Inc Recent Development Table 58. AstraZeneca PLC Company Information Table 59. AstraZeneca PLC Business Overview Table 60. AstraZeneca PLC Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. AstraZeneca PLC Anti-inflammatory Therapeutics Product Portfolio Table 62. AstraZeneca PLC Recent Development Table 63. Pfizer, Inc Company Information Table 64. Pfizer, Inc Business Overview Table 65. Pfizer, Inc Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer, Inc Anti-inflammatory Therapeutics Product Portfolio Table 67. Pfizer, Inc Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis Anti-inflammatory Therapeutics Product Portfolio Table 72. Novartis Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche Anti-inflammatory Therapeutics Product Portfolio Table 77. Roche Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck Anti-inflammatory Therapeutics Product Portfolio Table 82. Merck Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sanofi Anti-inflammatory Therapeutics Product Portfolio Table 87. Sanofi Recent Development Table 88. GlaxoSmithKline Company Information Table 89. GlaxoSmithKline Business Overview Table 90. GlaxoSmithKline Anti-inflammatory Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline Anti-inflammatory Therapeutics Product Portfolio Table 92. GlaxoSmithKline Recent Development Table 93. Sun Pharmaceutical Industries Ltd Company Information Table 94. Sun Pharmaceutical Industries Ltd Business Overview Table 95. Sun Pharmaceutical Industries Ltd Anti-inflammatory Therapeutics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 96. Sun Pharmaceutical Industries Ltd Anti-inflammatory Therapeutics Product Portfolio Table 97. Sun Pharmaceutical Industries Ltd Recent Development Table 98. TEVA Company Information Table 99. TEVA Business Overview Table 100. TEVA Anti-inflammatory Therapeutics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 101. TEVA Anti-inflammatory Therapeutics Product Portfolio Table 102. TEVA Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Anti-inflammatory Therapeutics Product Image Figure 2. Global Anti-inflammatory Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-inflammatory Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-inflammatory Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anti-inflammatory Biologics Image Figure 8. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Image Figure 9. Corticosteroids Image Figure 10. Others Image Figure 11. Global Anti-inflammatory Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Anti-inflammatory Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-inflammatory Therapeutics Sales Value Share by Type (2021-2032) Figure 14. Arthritis Image Figure 15. Respiratory Diseases Image Figure 16. Dermatology Image Figure 17. Gastroenterology Image Figure 18. Others Image Figure 19. Global Anti-inflammatory Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Anti-inflammatory Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-inflammatory Therapeutics Sales Value Share by Application (2021-2032) Figure 22. Global Anti-inflammatory Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Anti-inflammatory Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Anti-inflammatory Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. North America Anti-inflammatory Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Anti-inflammatory Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Anti-inflammatory Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Anti-inflammatory Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Anti-inflammatory Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Anti-inflammatory Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. South America Anti-inflammatory Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Anti-inflammatory Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Anti-inflammatory Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-inflammatory Biologics
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Others
Applications
  • Arthritis
  • Respiratory Diseases
  • Dermatology
  • Gastroenterology
  • Others
Companies covered
  • AbbVie
  • Johnson & Johnson
  • Amgen Inc
  • AstraZeneca PLC
  • Pfizer, Inc
  • Novartis
  • Roche
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • Sun Pharmaceutical Industries Ltd
  • TEVA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-inflammatory Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-inflammatory Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-inflammatory Therapeutics Market Dynamics
  1. 2.1 Anti-inflammatory Therapeutics Industry Trends
  2. 2.2 Anti-inflammatory Therapeutics Industry Drivers
  3. 2.3 Anti-inflammatory Therapeutics Industry Opportunities and Challenges
  4. 2.4 Anti-inflammatory Therapeutics Industry Restraints
3 Anti-inflammatory Therapeutics Market by Company
  1. 3.1 Global Anti-inflammatory Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Anti-inflammatory Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Anti-inflammatory Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Anti-inflammatory Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-inflammatory Therapeutics Company Product Type and Application
  6. 3.6 Global Anti-inflammatory Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-inflammatory Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-inflammatory Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-inflammatory Therapeutics Market by Type
  1. 4.1 Anti-inflammatory Therapeutics Type Introduction
  2. 4.1.1 Anti-inflammatory Biologics
  3. 4.1.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  4. 4.1.3 Corticosteroids
  5. 4.1.4 Others
  6. 4.2 Global Anti-inflammatory Therapeutics Sales Value by Type
  7. 4.2.1 Global Anti-inflammatory Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Anti-inflammatory Therapeutics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Anti-inflammatory Therapeutics Sales Value Share by Type (2021-2032)
5 Anti-inflammatory Therapeutics Market by Application
  1. 5.1 Anti-inflammatory Therapeutics Application Introduction
  2. 5.1.1 Arthritis
  3. 5.1.2 Respiratory Diseases
  4. 5.1.3 Dermatology
  5. 5.1.4 Gastroenterology
  6. 5.1.5 Others
  7. 5.2 Global Anti-inflammatory Therapeutics Sales Value by Application
  8. 5.2.1 Global Anti-inflammatory Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Anti-inflammatory Therapeutics Sales Value by Application (2021-2032)
  10. 5.2.3 Global Anti-inflammatory Therapeutics Sales Value Share by Application (2021-2032)
6 Anti-inflammatory Therapeutics Regional Value Analysis
  1. 6.1 Global Anti-inflammatory Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-inflammatory Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-inflammatory Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-inflammatory Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-inflammatory Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Anti-inflammatory Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-inflammatory Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-inflammatory Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-inflammatory Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-inflammatory Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-inflammatory Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Anti-inflammatory Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-inflammatory Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-inflammatory Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Anti-inflammatory Therapeutics Country-level Value Analysis
  1. 7.1 Global Anti-inflammatory Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-inflammatory Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-inflammatory Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-inflammatory Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-inflammatory Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-inflammatory Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-inflammatory Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Anti-inflammatory Therapeutics Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Anti-inflammatory Therapeutics Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Amgen Inc
  14. 8.3.1 Amgen Inc Company Information
  15. 8.3.2 Amgen Inc Business Overview
  16. 8.3.3 Amgen Inc Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc Anti-inflammatory Therapeutics Product Portfolio
  18. 8.3.5 Amgen Inc Recent Developments
  19. 8.4 AstraZeneca PLC
  20. 8.4.1 AstraZeneca PLC Company Information
  21. 8.4.2 AstraZeneca PLC Business Overview
  22. 8.4.3 AstraZeneca PLC Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca PLC Anti-inflammatory Therapeutics Product Portfolio
  24. 8.4.5 AstraZeneca PLC Recent Developments
  25. 8.5 Pfizer, Inc
  26. 8.5.1 Pfizer, Inc Company Information
  27. 8.5.2 Pfizer, Inc Business Overview
  28. 8.5.3 Pfizer, Inc Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer, Inc Anti-inflammatory Therapeutics Product Portfolio
  30. 8.5.5 Pfizer, Inc Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Anti-inflammatory Therapeutics Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Anti-inflammatory Therapeutics Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Merck
  44. 8.8.1 Merck Company Information
  45. 8.8.2 Merck Business Overview
  46. 8.8.3 Merck Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck Anti-inflammatory Therapeutics Product Portfolio
  48. 8.8.5 Merck Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Anti-inflammatory Therapeutics Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Anti-inflammatory Therapeutics Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Sun Pharmaceutical Industries Ltd
  62. 8.11.1 Sun Pharmaceutical Industries Ltd Company Information
  63. 8.11.2 Sun Pharmaceutical Industries Ltd Business Overview
  64. 8.11.3 Sun Pharmaceutical Industries Ltd Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceutical Industries Ltd Anti-inflammatory Therapeutics Product Portfolio
  66. 8.11.5 Sun Pharmaceutical Industries Ltd Recent Developments
  67. 8.12 TEVA
  68. 8.12.1 TEVA Company Information
  69. 8.12.2 TEVA Business Overview
  70. 8.12.3 TEVA Anti-inflammatory Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 TEVA Anti-inflammatory Therapeutics Product Portfolio
  72. 8.12.5 TEVA Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst